Kobina Dufu

2.0k total citations
32 papers, 1.4k citations indexed

About

Kobina Dufu is a scholar working on Genetics, Physiology and Molecular Biology. According to data from OpenAlex, Kobina Dufu has authored 32 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 14 papers in Physiology and 10 papers in Molecular Biology. Recurrent topics in Kobina Dufu's work include Hemoglobinopathies and Related Disorders (19 papers), Erythrocyte Function and Pathophysiology (12 papers) and Hemoglobin structure and function (8 papers). Kobina Dufu is often cited by papers focused on Hemoglobinopathies and Related Disorders (19 papers), Erythrocyte Function and Pathophysiology (12 papers) and Hemoglobin structure and function (8 papers). Kobina Dufu collaborates with scholars based in United States, United Kingdom and Australia. Kobina Dufu's co-authors include Robin Reed, Anusha P. Dias, Chung‐Sheng Lee, Hong Cheng, Donna Oksenberg, Mira Patel, Haixin Lei, Stuart A. Wilson, Athiwat Hutchaleelaha and Steven P. Gygi and has published in prestigious journals such as Cell, Circulation and Nature Communications.

In The Last Decade

Kobina Dufu

30 papers receiving 1.4k citations

Peers

Kobina Dufu

GENET

HEMAT

PHYSI

PPCH

Pascal Bailly France

Pascale Texier France

H. Daniel Lacorazza United States

Andrew J.K. Williamson United Kingdom

Kenneth E. Sahr United States

Françoise Durrieu France

Fiorella Ciaffoni Italy

James G. Stout United States

Jean‐Pierre Cartron France

Guy Cornu Belgium

Pascal Bailly France

Kobina Dufu

414 ×0.5

245 ×0.6

GENET

734 ×2.5

HEMAT

709 ×4.5

PHYSI

114 ×1.3

PPCH

Citations per year, relative to Kobina Dufu Kobina Dufu (= 1×) peers Pascal Bailly

Countries citing papers authored by Kobina Dufu

Since Specialization

Citations

This map shows the geographic impact of Kobina Dufu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kobina Dufu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kobina Dufu more than expected).

Fields of papers citing papers by Kobina Dufu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kobina Dufu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kobina Dufu. The network helps show where Kobina Dufu may publish in the future.

Co-authorship network of co-authors of Kobina Dufu

This figure shows the co-authorship network connecting the top 25 collaborators of Kobina Dufu. A scholar is included among the top collaborators of Kobina Dufu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kobina Dufu. Kobina Dufu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lisbon, Eleanor, R. Clark Brown, Andrew Redfern, et al.. (2025). Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients. Clinical Pharmacology & Therapeutics. 119(1). 120–130.

Dufu, Kobina, Carsten Alt, Steven Strutt, et al.. (2023). GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. British Journal of Haematology. 202(1). 173–183. 6 indexed citations

Idowu, Modupe, Thinh Nguyen, Derek Lewis, et al.. (2022). Pharmacodynamic Results from Phase 1 Studies of GBT021601, a Next-Generation HbS Polymerization Inhibitor for Treatment of Sickle Cell Disease. Blood. 140(Supplement 1). 24–25. 2 indexed citations

Stewart, Glenn M., Troy J. Cross, Michael J. Joyner, et al.. (2021). Impact of Pharmacologically Left Shifting the Oxygen–Hemoglobin Dissociation Curve on Arterial Blood Gases and Pulmonary Gas Exchange During Maximal Exercise in Hypoxia. High Altitude Medicine & Biology. 22(3). 249–262. 9 indexed citations

Dufu, Kobina, Carsten Alt, Steven Strutt, et al.. (2020). GBT021601 Inhibits HbS Polymerization, Prevents RBC Sickling and Improves the Pathophysiology of Sickle Cell Disease in a Murine Model. Blood. 136(Supplement 1). 7–8. 4 indexed citations

Howard, Jo, Claire Hemmaway, Paul Telfer, et al.. (2019). A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood. 133(17). 1865–1875. 84 indexed citations

Dufu, Kobina, David C. Rees, John Brewin, et al.. (2019). The effect of the antisickling compoundGBT1118 on the permeability of red blood cells from patients with sickle cell anemia. Physiological Reports. 7(6). e14027–e14027. 9 indexed citations

Dufu, Kobina, Mira Patel, Donna Oksenberg, & Pedro Cabrales. (2018). GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions. Clinical Hemorheology and Microcirculation. 70(1). 95–105. 61 indexed citations

Dufu, Kobina & Donna Oksenberg. (2018). GBT440 reverses sickling of sickled red blood cells under hypoxic conditions in vitro. Hematology Reports. 10(2). 7419–7419. 15 indexed citations

10.

Dufu, Kobina, et al.. (2016). GBT440 Inhibits Sickling of Sickle Cell Trait Blood under In Vitro Conditions Mimicking Strenuous Exercise. Hematology Reports. 8(3). 6637–6637. 13 indexed citations

11.

Howard, Jo, Claire Hemmaway, Moji Awogbade, et al.. (2016). Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor. Blood. 128(22). 2488–2488. 11 indexed citations

12.

Oksenberg, Donna, Kobina Dufu, Mira Patel, et al.. (2016). GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell disease. British Journal of Haematology. 175(1). 141–153. 184 indexed citations

13.

Cabrales, Pedro, et al.. (2015). Abstract 10826: GBT1118, a Potent Allosteric Modifier of Hemoglobin Oxygen Affinity Increases Tolerance to Hypoxia in Mice. Circulation. 132(suppl_3). 1 indexed citations

14.

Howard, Jo, Claire Hemmaway, Moji Awogbade, et al.. (2015). GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease. Blood. 126(23). 542–542. 20 indexed citations

15.

Folco, Eric G., Chung‐Sheng Lee, Kobina Dufu, Tomohiro Yamazaki, & Robin Reed. (2012). The Proteins PDIP3 and ZC11A Associate with the Human TREX Complex in an ATP-Dependent Manner and Function in mRNA Export. PLoS ONE. 7(8). e43804–e43804. 50 indexed citations

16.

Dufu, Kobina, et al.. (2010). ATP is required for interactions between UAP56 and two conserved mRNA export proteins, Aly and CIP29, to assemble the TREX complex. Genes & Development. 24(18). 2043–2053. 143 indexed citations

17.

Dias, Anusha P., Kobina Dufu, Haixin Lei, & Robin Reed. (2010). A role for TREX components in the release of spliced mRNA from nuclear speckle domains. Nature Communications. 1(1). 97–97. 147 indexed citations

18.

Cheng, Hong, et al.. (2006). Human mRNA Export Machinery Recruited to the 5′ End of mRNA. Cell. 127(7). 1389–1400. 372 indexed citations

19.

Das, Rita, et al.. (2006). Functional coupling of RNAP II transcription to spliceosome assembly. Genes & Development. 20(9). 1100–1109. 97 indexed citations

20.

Parker, Matthew H., Francis T. Danehy, Kobina Dufu, et al.. (2005). Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Engineering Design and Selection. 18(9). 435–444. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact